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Background: Deregulation of Wnt/β-catenin signaling is a hallmark of the majority of sporadic forms of colorectal
cancer and results in increased stability of the protein β-catenin. β-catenin is then shuttled into the nucleus where
it activates the transcription of its target genes, including the proto-oncogenes MYC and CCND1 as well as the
genes encoding the basic helix-loop-helix (bHLH) proteins ASCL2 and ITF-2B. To identify genes commonly regulated
by β-catenin in colorectal cancer cell lines, we analyzed β-catenin target gene expression in two non-isogenic cell
lines, DLD1 and SW480, using DNA microarrays and compared these genes to β-catenin target genes published in
the PubMed database and DNA microarray data presented in the Gene Expression Omnibus (GEO) database.
Results: Treatment of DLD1 and SW480 cells with β-catenin siRNA resulted in differential expression of 1501 and
2389 genes, respectively. 335 of these genes were regulated in the same direction in both cell lines. Comparison of
these data with published β-catenin target genes for the colon carcinoma cell line LS174T revealed 193 genes that
are regulated similarly in all three cell lines. The overlapping gene set includes confirmed β-catenin target genes like
AXIN2, MYC, and ASCL2. We also identified 11 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that
are regulated similarly in DLD1 and SW480 cells and one pathway – the steroid biosynthesis pathway – was
regulated in all three cell lines.
Conclusions: Based on the large number of potential β-catenin target genes found to be similarly regulated in
DLD1, SW480 and LS174T cells as well as the large overlap with confirmed β-catenin target genes, we conclude that
DLD1 and SW480 colon carcinoma cell lines are suitable model systems to study Wnt/β-catenin signaling and
associated colorectal carcinogenesis. Furthermore, the confirmed and the newly identified potential β-catenin target
genes are useful starting points for further studies.
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The majority of sporadic forms of colorectal cancer are
characterized by deregulation of Wnt/β-catenin signaling
resulting in increased transcriptional activity of the protein
β-catenin. In colon cells, a protein complex consisting of the
protein Adenomatous polyposis coli (APC), the scaffolding
protein Axin, casein kinase 1 (CK-1) and glycogen synthase
kinase 3β (GSK-3β) tightly controls the transcriptional* Correspondence: Andreas.Herbst@med.uni-muenchen.de
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reproduction in any medium, provided the oractivity of the β-catenin protein by targeting it for proteaso-
mal degradation. Stimulation of colon cells with Wnt pro-
teins results in the disruption of the APC protein complex
and stabilization of the β-catenin protein. β-catenin is then
transported into the nucleus where it recruits cofactors of
the TCF/LEF family to activate the transcription of its target
genes [1]. In colorectal tumor cells, the tumor suppressor
gene APC is frequently affected by loss of heterozygosity
(LOH) as well as mutations, resulting in inactivation of
the APC protein complex targeting β-catenin for degrad-
ation [2,3]. Consequently, β-catenin activity is deregulated
and promotes aberrant transcription of its target genes [1].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Validation of β-catenin siRNA. DLD1 and SW480 cells
were treated with β-catenin siRNA (siβcat) or β-galactosidase siRNA
(siβgal) and the protein expression levels of β-catenin were
determined by immuno detection using an anti-β-catenin antibody.
Actin was used as a loading control (A). The activity of the β-catenin
dependent reporter gene 8×TOPflash was determined in DLD1 and
SW480 cells after treatment of these cells with β-catenin siRNA or
β-galactosidase siRNA. The experiments were performed in
duplicates with error bars representing standard deviation (B).
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ing different cellular processes including proliferation
(e.g., MYC, CCND1, PPARD), stem cell fate (ASCL2), sur-
vival (ABCB1, BIRC5), differentiation (ID2, ITF2, ENC1),
migration (MMP7, MMP14), and angiogenesis (VEGF)
[4-18]. While these β-catenin functions play an important
role in embryonic development and tissue homeostasis,
they can also contribute to the initiation and progression
of colon cancer. In particular, deregulation of genes in-
volved in proliferation and migration is frequently ob-
served in colorectal carcinomas [5-7,14-16].
Genes encoding members of the basic helix-loop-helix
(bHLH) family of proteins, like ASCL2, HATH1, and ITF2,
represent one of the largest groups of genes on the list of
previously published β-catenin target genes [8,19,20]. Mem-
bers of the bHLH protein family are characterized by the
presence of a basic DNA binding domain and a HLH
protein-protein interaction domain. Based on their primary
sequence, bHLH proteins are grouped into seven classes
and are known to form homo- and heterodimers to regu-
late their functions [21]. For example, the class I bHLH
protein ITF-2B encoded by the gene ITF2 is known to
interact with class II and class V bHLH proteins [22].
The colon carcinoma cell lines, DLD1 and SW480, are
frequently used as model systems to study colorectal car-
cinogenesis in general and β-catenin function in particular.
To identify target genes that are commonly regulated by
β-catenin, we chose these non-isogenic colorectal cancer
cell lines for our experiments. While DLD1 cells are de-
rived from a microsatellite instable (MSI) tumor, SW480
tumor cells are characterized by chromosomal instability
(CIN) [23]. In both cell lines the APC gene is affected by
LOH on chromosome 5 and contains inactivating muta-
tions in the remaining APC allele [24]. In contrast, the
MSI colon carcinoma cell line LS174T –that was used for
validation purposes– expresses wild-type APC and a mu-
tated β-catenin protein [23,24].
Here, we analyzed the gene expression profiles of DLD1
and SW480 cells after down regulation of β-catenin ex-
pression and compared the potential β-catenin target
genes that are similarly regulated in DLD1 and SW480
cells with a comparable data set published for LS174T cells
in the Gene Expression Omnibus (GEO) database as well
as confirmed β-catenin target genes found in the PubMed
database. We also identified 11 Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways that are regulated
similarly in DLD1 and SW480 cells. In addition, one
KEGG pathway was regulated in all three cell lines. Based
on the large number of genes that are regulated in a simi-
lar way in DLD1, SW480, and LS174T cells as well as the
large overlap with previously published β-catenin target
genes, we conclude that DLD1 and SW480 are good
model systems to study β-catenin target genes and signal-
ing pathways. Furthermore, we were able to confirm alarge number of previously published β-catenin target
genes and identified many new potential β-catenin target
genes. Therefore, this data is a useful resource for further
studies to elucidate the role of β-catenin signaling in colo-
rectal cancer.Results
Identification of β-catenin target genes in DLD1 and
SW480 colon carcinoma cells
To test the efficacy of the β-catenin siRNA used for our
DNA microarray experiments, DLD1 and SW480 cells
were treated with this β-catenin siRNA and β-catenin pro-
tein expression was analyzed using immuno detection.
Since we observed the strongest down regulation of β-
catenin protein after siRNA treatment for 48 hrs, cells were
treated for this period of time. Compared to DLD1 and
SW480 cells treated with control siRNA (siβgal), treatment
with β-catenin siRNA (siβcat) attenuated β-catenin protein
expression levels in both cell lines (Figure 1A). Similarly,
treatment of DLD1 and SW480 cells with β-catenin siRNA
strongly reduced the activity of the β-catenin dependent
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cacy of the β-catenin siRNA (Figure 1B).
To identify commonly regulated β-catenin target genes
in colorectal cancer cell lines, we analyzed the expression
of β-catenin target genes in DLD1 and SW480 cells after
siRNA treatment of these cells using DNA microarrays.
Treatment of DLD1 and SW480 cells with siRNA target-
ing β-catenin resulted in differential expression of 1501
and 2389 genes, respectively (Figure 2A and Additional
file 1, tab “DLD1 complete” and “SW480_complete”). The
intersecting set comprised 335 genes, which are regulated
in the same direction in both cell lines (Figure 2A and
Additional file 1, tab “335 target genes”). We compared
the lists of potential β-catenin target genes obtained for
DLD1 and SW480 cells to a previously published data set
containing differentially expressed genes after treatment of
the colon carcinoma cell line LS174T with β-catenin
shRNA. Out of the 5543 differentially expressed genes in
LS174T cells (Additional file 1, tab “LS174T_complete”),
786 genes and 677 genes were regulated similarly in DLD1
and SW480 cells, respectively. Furthermore, we identified
193 genes that are regulated in the same direction in all
three cell lines (Figure 2A and Additional file 1, tab
“DLD1_SW480_LS174T_only”).
Out of the 193 genes that are up or down regulated in
DLD1, SW480, and LS174T cells, 4 genes (ASCL2, AXIN2,
MYC, and S100A6) have previously been described as β-
catenin target genes (compare Table 1 and Additional file 1,
tab “DLD1_SW480_LS174T_only”; This tab also contains
the false discovery rate (FDR) as well as the fold change
(FC) for each gene). In addition, we identified the genes
ABCB1, CD44, FGF18, and HEF1 (NEDD9) as potential β-
catenin target genes in DLD1 and SW480 cells (Additional
file 1, tab “335 target genes”; This tab also contains the false
discovery rate (FDR) as well as the fold change (FC) for
each gene).
Based on a literature search in the PubMed database,
we identified 33 genes that are regulated in a β-catenin
dependent manner in addition to the 33 β-catenin target
genes published by Roel Nusse. (All these genes are dif-
ferentially regulated either in normal colon, colon car-
cinoma cells, or colon carcinoma cell lines.) 38 out of
these 66 genes are directly regulated by β-catenin as
demonstrated by ChIP, EMSA, or RGA with mutated
(canonical) TCF4 binding sites (Table 1). When we re-
analyzed the microarray data focusing our analysis only
on the list of these 66 previously published β-catenin tar-
get genes, we identified 21 (DLD1), 30 (SW480), and 34
(LS174T) of these genes as differentially regulated in the
three cell lines, respectively (Figure 2B and Additional file 2).
The genes ASCL2, AXIN2, MYC, NOTCH2, S100A6, and
SP5 were regulated in DLD1, SW480, and LS174T cells.
Moreover, we found that the genes ABCB1, CD44,
FGF18, HEF1 (NEDD9), and ITF2 (TCF4) were alsodifferentially regulated in DLD1 and SW480 cells (see
Additional file 2, “DLD1_SW480_LS174T_only” and tab
“DLD1_SW480_complete”). Thus, our second analysis
using a limited number of genes confirmed our first
microarray analysis using all differentially expressed genes
and identified the genes ITF2 (TCF4), NOTCH2 and SP5
as β-catenin target genes in addition to ABCB1, ASCL2,
AXIN2, CD44, FGF18, MYC, HEF1 (NEDD9), and
S100A6 found in the first analysis.
Due to the large number of genes encoding members
of the basic helix-loop-helix (bHLH) family of proteins
among the list of β-catenin target genes (6 out 66 genes;
Table 1), we were interested in identifying more mem-
bers of this family of genes in our microarray data set.
When we re-analyzed the microarray data limiting our
analysis to the 96 bHLH proteins listed in the PFAM data-
base, we identified the genes ASCL2 and MYC as differen-
tially regulated in DLD1, SW480, and LS174T cells (see
Additional file 3, tab “DLD1_SW480_LS174T_only”). In
DLD1 and SW480 cells, the genes ID1, and ITF2 (TCF4)
were also differentially regulated (Figure 2C and Additional
file 3, tab “DLD1_SW480_complete”). Taken together, out
of the six β-catenin target genes belonging to the bHLH
family of proteins (Table 1), three genes (ASCL2, ITF2
(TCF4), MYC) are commonly regulated in DLD1 and
SW480 cells.
Using the software package “Cytoscape” in combination
with the “Michigan Molecular Interactions” (MiMI) plu-
gin, we searched the list of 193 genes that are differentially
regulated in DLD1, SW480, and LS174T cells for known
interactions. We identified three networks that contained
three or more nodes (genes) (Figure 3A). The largest net-
work centered on β-catenin comprised 18 genes, while the
second largest network with 6 genes contained the gene
YWHAZ encoding the 14-3-3 protein isoforms ξ/δ at its
center. The smallest network contained the three nodes
NET1, ARHGAP29, and DEPDC7 (Figure 3A). When we
focused our analysis on the list of 335 genes that are differ-
entially regulated in DLD1 and SW480 cells, we identified
the same three networks that we found in the intersection
of DLD1, SW480, and LS174T cells. However, the network
centered on β-catenin was increased to 36 genes, while
the network containing the gene YWHAZ comprised two
additional nodes (8 in total). The smallest network con-
tained the four nodes NET1, ARHGAP29, ABR and
DEPDC7 (Figure 3B). Interestingly, both panels highlight
the β-catenin target gene MYC as a major player with 10
and 19 directly regulated genes, respectively (Figure 3A
and B).
Apart from identifying potential β-catenin target genes,
we were interested to find out if particular signaling path-
ways or cellular functions are regulated by β-catenin. We
used the gene set enrichment software (GSEA) software
[80,81] to identify pathways associated with β-catenin
Figure 2 Identification of β-catenin target genes. DLD1 and
SW480 cells were treated with β-catenin siRNA and differentially
expressed genes were identified using a DNA microarray. The
corresponding data for LS174T cells was published earlier and used
for comparison. The Venn-like diagrams display the number of
differentially expressed genes when analyzing all differentially
expressed genes (A), previously described β-catenin target genes
listed in Table 1 (B), or 96 genes encoding basic helix-loop-helix
(bHLH) proteins (PFAM family PF00010) (C). The names of the genes
corresponding to the seven sections of each Venn-like diagram are
listed in separate tabs in the Additional files 1, 2 and 3.
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control siRNA 2 KEGG pathways were enriched. These
pathways comprised the glycine, serine and threonine
metabolism as well as the renin angiotensin system. After
down regulation of β-catenin expression levels, the follow-
ing 9 KEGG pathways were enriched in DLD1 and SW480
cells: endocytosis, insulin signaling pathway, lysosome fc
gamma r mediated phagocytosis, apoptosis, regulation of
actin cytoskeleton, adipocytokine signaling, glycerolipid
metabolism, lysosome and aldosterone regulated sodium
reabsorption (Table 2). In addition, the steroid hormone
biosynthesis pathway was enriched in DLD1, SW480, and
LS174Tcells after treatment with β-catenin siRNA (Table 2).
Apart from the KEGG pathway database, we also used the
Biocarta pathway database in the gene set enrichment ana-
lysis. Down regulation of β-catenin resulted in the enrich-
ment of the M-calpain pathway, the Creb pathway, and the
IGF1R pathway in DLD1 and SW480 cells (Additional files
4 and 5).
Discussion
β-catenin plays a crucial role in embryogenesis, tissue
homeostasis and carcinogenesis. Because of its role in
regulating homeostasis of the intestinal tract as well as be-
ing a key player in sporadic forms of colorectal cancer, in-
hibition of β-catenin is not a suitable strategy to treat
patients with colorectal cancer. For this reason, identifying
and characterizing β-catenin target genes could result in
better understanding of colorectal carcinogenesis and de-
velopment of new therapies. Here, we used two non-
isogenic colorectal cancer cell lines, DLD1, and SW480,
and identified 335 commonly regulated β-catenin target
genes. 193 of these genes were also differentially regulated
in LS174T cells. (Genes that are differentially expressed
due to the genetic background of a given cell should be
deregulated to a similar extent irrespective of the siRNA
treatment and hence should not appear as being differen-
tially regulated in the DNA microarray experiment.) Com-
pared to the number of differentially regulated genes in
LS174T and DLD1 cells (786 genes) as well as in LS174T
and SW480 cells (677 genes), the number of commonly
regulated genes in DLD1 and SW480 (335 genes) was low,
resulting in a low number of commonly regulated genes in








ABCB1 ABC multidrug transporter Yes EMSA, RGA w/ mutated
reporter gene
Up [9]
ADAM10 Disintegrin and metalloproteinase
domain-containing protein 1a
Not analyzed RGA Up [25]
ALEX1 Armadillo repeat-containing
X-linked protein 1
Not analyzed RGA, ChIP for CREB; activation
mediated by CREB (CRE) und E
boxes within the ALEX1 promoter
Up [26]
ASCL2 Achaete-scute homolog 2 Not analyzed qRT-PCR Up [8]
AXIN2* Axin-2 Not analyzed RGA Up [27-29]
BAMBI BMP and activin
membrane-bound inhibitor
Yes RGA w/ mutated reporter gene [30]
BCL2L2 Bcl-2-like protein 2; BCLW Yes ChIP Up [31]
BIRC5* Survivin, Baculoviral IAP
repeat-containing protein 5
Yes EMSA, RGA w/ mutated reporter gene Up [10]
BMI1 Polycomb complex protein BMI-1 Not analyzed RGA Up [32]
BMP4* Bone morphogenetic protein 4 Not analyzed Northern blot Up [33]
CCND1* Cyclin-D1 Yes EMSA Up [5,6]
CD44* CD44 antigen Not analyzed – Up [34,35]
CDKN2A p16INK4a Yes ChIP Up [36]
CDX1 Homeobox protein Cdx-1 Yes RGA w/ mutated reporter gene Up [37]
CLDN1* Claudin-1 Yes RGA Up [38]
COX2 cyclooxygenase-2 Yes EMSA, RGA w/ mutated reporter gene Up [39]
DKK1* Dickkopf-1 Yes EMSA Up [40]
DKK4* Dickkopf-4 Not analyzed RGA, siRNA/qRT-PCR Up [41,42]
DNMT1 DNA methyltransferase 1 Not analyzed RGA Up [43]
EDN1* endothelin-1 Yes ChIP Up [44]
EFNB1* Ephrin-B1 Not analyzed Northern blot Down [45]
ENC1 ectodermal-neural cortex 1 Yes RGA w/ mutated reporter gene Up [13]
EPHB2 Ephrin type-B receptors Not analyzed Northern blot Up [45]
EPHB3 Ephrin type-B receptors Not analyzed Northern blot Up [45]
FGF18* Fibroblast growth factor 18 Yes EMSA Up [45,46]
FGFBP Fibroblast growth
factor-binding protein
Yes RGA w/ mutated reporter gene Up [47]
FRA1* Fos-related antigen 1 Yes EMSA Up [48]
FSCN1 Fascin1 Yes ChIP Up [49]
GAST* Gastrin Not analyzed RGA Up [50]
HATH1* human ortholog of atonal1 Not analyzed RGA Down [19]
HEF1
(NEDD9)
human enhancer of filamentation 1 Yes ChIP Up [51]
HES1 Hes1 (Hairy and enhancer of split 1) Yes RGA w/ mutated reporter gene Up [52]
ID2* DNA-binding protein inhibitor ID-2 Yes EMSA Up [11,12]
ITF2 (TCF4)* Immunoglobulin transcription factor 2 Not analyzed RGA Up [20]
JAG1* Jagged-1 Yes ChIP Up [53]
JUN* Transcription factor AP-1 Yes EMSA Up [48]
L1CAM* L1 neuronal cell adhesion molecule Yes EMSA Up [54]
LAMC2 Laminin subunit gamma-2 Yes EMSA, RGA w/ mutated reporter gene Up [55]
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Table 1 β-catenin target genes in human colon or colon carcinoma cells (including colon carcinoma cell lines)
(Continued)
LEF1* Lymphoid enhancer-binding factor 1 Yes DNAse footprint, ChIP Up [56-58]
LGR5* Leucine-rich repeat-containing
G-protein coupled receptor 5
Not analyzed – Up [59]
MENA ENAH, Mammalian enabled homologue Yes ChIP Up [60]
MET* Hepatocyte growth factor receptor Not analyzed – Up [61]
MMP14 Matrix metalloproteinase-14
(old name: MT1-MMP)
Yes EMSA, RGA w/ mutated reporter gene Up [16]
MMP7* Matrilysin Not analyzed RGA Up [14,15]
MYB Transcriptional activator Myb Not analyzed Northern blot Up [62]
MYC* Myc proto-oncogene protein Yes EMSA Up [4]
MYCBP* c-myc binding protein Not analyzed RGA Up [63]
NOS2* Nitric Oxide Synthase 2 Yes EMSA Up [64]
NOTCH2 NOTCH2 protein Yes EMSA, RGA w/ mutated reporter gene Up [65]
NRCAM* Neuronal cell adhesion molecule Not analyzed RGA Up [66]
PLAU* urokinase plasminogen activator Yes EMSA Up [67]
PLAUR urokinase-type plasminogen activator
receptor
Not analyzed – Up [48]
PPARD* PPARdelta Yes EMSA Up [7]
S100A4 Protein S100-A4 Yes Chip, EMSA, RGA w/ mutated reporter
gene
Up [68]
S100A6 Protein S100-A6 Not analyzed RGA Up [69]
SGK1 Serum/glucocorticoid-regulated kinase 1 Yes ChIP Up [70]
SMC3 Structural maintenance of
chromosomes protein 3
Yes EMSA, RGA w/ mutated reporter gene Up [71]
SOX9* Transcription factor Sox-9 Not analyzed Northern blot Up [72]
SP5 Transcription factor Sp5 Yes EMSA Up [73]
SRSF3
(SRp20)
Serine/arginine-rich splicing factor 3 Not RGA Up [74]
SUZ12 Polycomb protein SUZ12 Yes ChIP, EMSA Up [75]
TCF1* Transcription factor 7 Not analyzed RGA Up [76]
TIAM1* TIAM-1 Not analyzed Northern blot Up [77]
TN-C Tenascin-C Yes ChIP Up [78]
VEGF* Vascular endothelial growth factor Not analyzed RGA Up [17]
YAP Yes-associated protein Yes ChIP Up [79]
Based on a PubMed search, we identified 66 β-catenin target genes. Nusse et al. have previously reported 33 of these genes on their web site. (http://www.stan-
ford.edu/group/nusselab/cgi-bin/wnt/target_genes; these genes are marked with an asterisk.). The gene and protein names follow the naming convention of the
Swiss-Prot database (http://www.uniprot.org). A regulation of a given target gene by β-catenin had to be confirmed by chromatin immune precipitation (ChIP),
electrophoretic mobility shift assay (EMSA), or reporter gene assays (RGA) with mutated TCF binding sites to be classified as “direct”.
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DLD1 and SW480 cells both express a mutated form of
APC, they differ with respect to the underlying genetic
disturbance: DLD1 cells show microsatellite instability
(MSI), whereas SW480 cells are derived from a tumor
with chromosomal instability (CIN). However, SW480
cells (CIN) share a lot of commonly regulated genes
with LS174T cells (MSI), suggesting that other factors
apart from genetic instability contribute to the ob-
served differences in gene expression between DLD1and SW480 cells. Looking at the mutational status,
DLD1, SW480, and LS174T cells differ with respect to
the status of the genes APC, PI3K, and TP53, but they
are identical with respect to status of the genes KRAS
and PTEN: DLD1 (APC: Mutant; TP53: WT; PI3K:
Mutant; KRAS: Mutant; PTEN: WT), SW480 (APC:
Mutant; TP53: Mutant; PI3K: WT; KRAS: Mutant;
PTEN: WT), and LS174T cells (APC: WT; TP53:
Mutant; PI3K: Mutant; KRAS: Mutant; PTEN: WT)
[82,83].
Figure 3 Identification of known interactions between differentially expressed β-catenin target genes in DLD1, SW480, and LS174T
cells. Using the software package “Cytoscape” in combination with the “MiMI” plugin, we identified known interactions between the 193
differentially expressed β-catenin target genes in DLD1, SW480, and LS174T cells (A) and the 335 differentially expressed β-catenin target genes
in DLD1 and SW480 cells (B). Only gene networks are displayed that contain three or more nodes. The genes highlighted in pink color have been
previously described as β-catenin target genes (see Table 1).
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DLD1 and LS174T) has been implicated in the phos-
phorylation of β-catenin at Ser552 [84], thereby promot-
ing nuclear accumulation and enhancing β-catenin
dependent transcriptional activity even in the absence of
aberrant Wnt signaling [85,86]. This observation sug-
gests that in particular LS174T cells that express wild-type APC could benefit from a mutation in the PI3K gene.
But even DLD1 cells (with mutant APC) could profit from
PI3K mutations: Deming et al. demonstrated that expres-
sion of a dominant active form of PI3K in ApcMin/+ mice
resulted in an increased tumor number and size and im-
plicated the CCND1 gene as one transcriptional target
that contributes to the observed phenotype of these mice
Table 2 Identification of signaling pathways enriched in more than one cell line
Treatment Intersection Enriched KEGG pathways Biocarta pathways
β-catenin RNAi DLD1/SW480 Endocytosis mCalpain pathway
Insulin signaling pathway CREB pathway
Lysosome IGF1R pathway
FC gamma R mediated phagocytosis
Apoptosis
Regulation of actin cytoskeleton
Glycerolipid metabolism
Focal adhesion
Aldosterone regulated sodium reabsorption
DLD1/LS174T PPAR signaling pathway –
Metabolism of xenobiotics by cytochrome P450
Butanoate metabolism
SW480/LS174T Complement and coagulation cascades
Histidine metabolism
Ether lipid metabolism
NOD like receptor signaling pathway
DLD1/SW480/LS174T Steroid hormone biosynthesis –
β-galactosidase RNAi DLD1/SW480 Glycine serine and threonine metabolism –
Renin angiotensin system










SW480/LS174T Basal cell carcinoma –
DLD1/SW480/LS174T –
Gene set enrichment analyses were performed after treatment of DLD1, SW480, and LS174T cells with β-catenin RNAi or β-galactosidase RNAi using the KEGG and
the Biocarta pathway database, respectively. Pathways that were enriched in more than one cell line were identified using a Biovenn software package.
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were up regulated in LS174T cells, but not in DLD1 cells.
The tumor suppressor p53 has been implicated in
down-regulating β-catenin expression and/or activity by
Siah-1 dependent (and GSK-3β independent) degrad-
ation [88,89], reduction of TCF4 mRNA and protein
levels [90] as well as reduction of β-catenin mRNA by
p53 dependent regulation of miRNA miR-34 [91]. Ac-
cordingly, inactivation of the transcriptional activity of
p53 by mutations –as observed in SW480 cells– should
result in increased β-catenin mRNA and protein levels
and transcriptional activity as well as increased mRNA
and protein levels of TCF4 (TCF7L2). Interestingly,LS174T cells showed a strong increase in the fold
change value for CTNNB1 (encoding β-catenin) (4,56
versus 1,59 (DLD1) and 1,18 (SW480), respectively). All
three cell lines showed slightly reduced fold change
values for TCF4 (TCF7L2). The effect of p53 inactiva-
tion on the development of intestinal adenomas was also
analyzed in ApcMin/+ mice: Despite the fact that p53 pro-
tein expression is deregulated as a consequence of APC
loss (and probably other factors) and p53 is known to
regulate β-catenin expression via a negative feedback loop,
loss of p53 did not promote the initial steps of intestinal
neoplasia in ApcMin/+ mice [92], suggesting that p53 has
only a limited role in this mouse model.
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levels via proteasomal degradation, (nuclear) APC has
been implicated in affecting β-catenin activity by recruit-
ing co-repressors of β-catenin to promoter regions, as well
as sequestering and enhancing the nuclear export of β-
catenin [93-96]. Mutated forms of APC still show a nu-
clear localization, but they are more frequently observed
in the cytoplasm when compared to wild-type APC, sug-
gesting that mutation of APC is not only contributing to
higher β-catenin protein expression levels, but also con-
tribute to enhanced β-catenin activity [97]. When Zeineldin
et al. generated mice expressing APC with mutated nu-
clear localization signals (mNLS) and compared these
ApcmNLS/mNLS mice with Apc+/+ mice, they found up regu-
lation of the mRNA for the genes AXIN2, MYC, and
CCDN1 as well as down regulation of HATH1 mRNA in
response to stimulation with Wnt [98]. Accordingly, we
expected an increase in the fold change values for AXIN2,
MYC, and CCDN1 transcripts as well as a reduction of
HATH1 transcripts in DLD1 and SW480 cells (APC mu-
tated) compared to LS174T (APC wild-type). In our ex-
periments, DLD1 and SW480 showed a modest increase
in the fold change values for MYC (see Additional file 1,
tab “DLD1_SW480_LS174T_only”) compared to LS174T
cells. However, LS174T (and SW480) cells responded with
a higher fold change for AXIN2 compared to DLD1 cells.
CCND1 transcript levels were increased only in LS174T
cells, whereas HATH1 transcript levels did not changed in
any of three cell lines.
The differential expression of the genes AXIN2 and
CCND1 in the three colorectal cancer cell lines high-
lights the fact that the genetic background of a given cell
has a major impact on the expression of a specific gene.
However, linking a specific somatic mutation in a tumor
suppressor gene or proto oncogene, e.g. APC, PI3K, or
TP53, to these differences in expression is difficult be-
cause the expression of a specific gene is affected by
multiple transcription factors (along with their cofactors
and corepressors). Therefore, we are not able to attribute
the observed differences in the gene expression profiles
for DLD1 and SW480 to a single mutation.
Compared to LS174T cells, the total number of differ-
entially regulated β-catenin target genes was much lower
in DLD1 and SW480 cells. This could be either specific
to the genetic background of the cell lines used or due
to different experimental approaches. While we transi-
ently transfected DLD1 and SW480 cells with β-catenin
siRNA and analyzed the gene expression 48 hours after
transfection, Mokry et al. [99] stably transfected LS174T
cells with a doxycycline inducible expression vector en-
coding β-catenin shRNA and stimulated the cells for 72
hours with doxycycline before analyzing the gene ex-
pression profile. Both research groups used Affymetrix
Human Genome U133 Plus 2.0 DNA microarrays fortheir experiments. The longer incubation period used to
identify potential β-catenin target genes in LS174T cells
might contribute to secondary effects like the differential
expression of indirect β-catenin target genes, thus
explaining why the absolute number of differentially reg-
ulated genes was higher in LS174T cells when compared
to DLD1 and SW480 cells. For this reason, we were par-
ticularly interested in genes that are up and down regu-
lated in the non-isogenic colorectal cancer cell lines
DLD1 and SW480 or DLD1, SW480, and LS174T cells,
assuming that these genes are commonly and directly
regulated by β-catenin.
Remarkably, the number of β-catenin regulated genes
was very similar in the three cell lines when focusing on
the list of 66 previously described β-catenin target genes.
Here, DLD1, SW480 and LS174T cells differentially regu-
lated 21, 30 and 34 of these genes, respectively. There are
at least two reasons why the number of detected β-catenin
target genes did not include (almost) all 66 β-catenin tar-
get genes presented in Table 1. First, the detection of β-
catenin target genes is dependent on the cellular context.
DLD1, SW480, and LS174T represent colorectal cancer
cell lines. Therefore, the expression pattern of β-catenin
target genes in these cells is likely to differ from β-catenin
target genes found in healthy colon cells, colonic aden-
omas, or metastatic colonic cells that are also listed in
Table 1. Second, the gene expression profile was analyzed
48 and 72 hours after beginning with the RNAi treatment,
respectively. Different periods of time influence the identi-
fication of β-catenin target genes as well, since some of
these genes might be regulated only for a short period of
time immediately after induction of β-catenin activity.
This phenomenon has been described by Van de Wetering
et al. (2002): They transfected LS174T cells with doxycyc-
line (Dox) inducible expression vectors encoding dnTCFs
and analyzed the changes in gene expression using DNA
microarrays. 11 h after treatment with Dox, 2411 genes
where differentially regulated. After an incubation period
of 23 h, they identified 1199 differentially regulated genes.
Comparison of the two sets of genes revealed that the ex-
pression of 1971 genes was abrogated between 11 and
23 h after Dox treatment, while 759 additional genes ap-
peared in this time frame [62]. Similarly, another group
analyzed the gene expression profiles of several known β-
catenin target genes in a time-course experiment and clas-
sified these genes according to their expression profiles
[100]. Based on this criterion, they identified genes that
were “immediately up (or down) regulated”, “early up
(down)”, or “late up (down)” in response to the activation
of the Wnt/β-catenin signaling cascade. When comparing
their results to the regulation of the same genes in differ-
ent cellular contexts, this group found that the regulation
of these genes was similar, but not necessarily identical in
different cell lines. This observation suggests that the
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tor and its cofactors (or co-repressors) influence the start-
ing point and duration of the gene expression of a specific
target gene. Therefore, it is recommendable to identify tar-
get genes of a given transcription factor in different cell
lines at least at the same time points, better yet in a time-
course experiment.
Using the KEGG pathway database, we identified 11 sig-
naling pathways or cellular functions in DLD1 and SW480
cells that are differentially regulated in response to treat-
ment of the colorectal cancer cell lines with β-catenin
siRNA. In addition, the steroid hormone biosynthesis path-
way was similarly regulated in all three cell lines analyzed.
Whereas the steroid hormone biosynthesis pathway
[101,102] as well as the endocytosis pathway [103,104], the
insulin signaling pathway [105,106], apoptosis [107,108],
regulation of the actin cytoskeleton [49], and focal adhesion
[109], have been associated with Wnt/β-catenin signaling,
there are no publications in the PubMed database linking
β-catenin to the remaining six pathways in colorectal can-
cer cells. Interestingly, the list of KEGG pathways/functions
did not include the canonical Wnt signaling pathway. This
was probably due to the definition of the “KEGG Wnt sig-
naling pathway” that summarized the canonical, the planar
cell polarity (PCP), and the Wnt/Ca2+ signaling pathway
under one database entry, despite different functions of
these signaling pathways. While the canonical Wnt pathway
has been implicated in regulating the activity of the β-
catenin protein, PCP signaling results in remodeling of the
cytoskeleton that is a prerequisite for migration and cell
polarization via the GTPases RHOA and RAC1. Wnt/Ca2+
signaling, however, plays a role in the regulation of cell ad-
hesion and cell movements during gastrulation and results
in the activation of protein kinase (PKC), calcium calmodu-
lin mediated kinase II (CAMKII) and calcineurin [110].
Furthermore, all three Biocarta pathways that were
enriched in DLD1 and SW480 cells have been associated
with Wnt/β-catenin signaling based on PubMed publica-
tions: the m-calpain pathway [111,112], the Creb path-
way [26,113], and the IGF1R pathway [114,115].
Since 6 out of the 66 previously described β-catenin tar-
get genes encode proteins that belong to the bHLH protein
family (Table 1), we focused our analysis on this group of
genes. Our analysis revealed that the genes ASCL2, ID1,
ITF2, and MYC were regulated in a β-catenin dependent
manner in DLD1 and SW480 cells. Interestingly, the pro-
teins ASCL2 and ITF-2B as well as ID1 and ITF-2B are
known to interact with each other [116,117], suggesting
that these bHLH proteins form a functional network in
colorectal carcinoma cells.
Conclusions
In conclusion, by comparing potential β-catenin target
genes in DLD1 and SW480 cells with 1) correspondingdata from LS174T cells and 2) a list of previously identi-
fied β-catenin target genes, we found and confirmed a
large number of β-catenin target genes, suggesting that
DLD1 and SW480 (as well as LS174T cells) are suitable
for identifying β-catenin target genes as well as β-
catenin dependent signaling pathways and functions.
Therefore, the presented list of commonly regulated
genes in DLD1 and SW480 cells as well as the annotated
list of previously published β-catenin target genes are
useful resources for further studies.
Methods
Cell culture
The colon carcinoma cell lines DLD1 and SW480 were
obtained from ATCC (Manassas, VA, USA) and were
cultured in DMEM medium supplemented with 10%
calf serum (PAA, Pasching, Austria). Short interfering
RNAs targeting β-catenin (cat. no. D-003482-04) and β-
galactosidase (cat. no. D-012539-01) were purchased
from Dharmacon (Lafayette, CO, USA) as siGenome
siRNAs. Cells were transfected with these siRNAs using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Immuno detection
Cell lysates were prepared with reporter gene lysis buffer
(Promega, Mannheim, Germany) supplemented with
protease inhibitor cocktail I (Calbiochem, Darmstadt,
Germany). Equal amounts of protein were mixed with 2×
SDS loading buffer (0.35 M Tris, pH 6.8; 30% (v/v) gly-
cerol; 10% (w/v) SDS; 100 mM Dithiothreitol; 0.01% (w/v)
bromphenol blue), separated by electrophoresis in discon-
tinuous SDS-polyacrylamide gels and transferred to
Immobilon-P membranes (Millipore, Billerica, MA, USA).
Antibodies specific for β-catenin (BD Transduction Labs,
San Jose, CA, USA), β-actin (MP Biomedicals, Eschwege,
Germany) and the secondary horseradish peroxidase-
conjugated goat anti-mouse antibody (GE Healthcare,
Freiburg, Germany) were used for immuno detection.
Blots were subjected to Supersignal West Dura chemilu-
minescence substrate (Thermo Scientific, Rockford, IL,
USA) and exposed to Fuji Medical x-ray film SuperRX
(FujiFilm).
Reporter gene assays
For reporter gene assays, 105 DLD1 or SW480 cells were
seeded per well (12 well plate). Cells were transfected
with the indicated siRNAs using Lipofectamine 2000
(Life Technologies). 24 hours later, the 8×TOPflash re-
porter gene construct (a generous gift from Randall T.
Moon, University of Washington) as well as the plas-
mid pCH110 encoding β-galactosidase (GE Healthcare,
Freiburg, Germany) were transfected into these cells. 72
hours after the siRNA transfection, cells were harvested,
lysed with reporter lysis buffer (Promega) and luciferase
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(Promega) and a luminometer (Orion II, Berthold Detec-
tion Systems, Wildbad, Germany). β-galactosidase
activity was determined by standard methods using o-
Nitrophenyl β-D-galactopyranoside (ONPG, Sigma-Aldrich,
Taufkirchen, Germany) as a control for transfection
efficiency.
Microarray analysis
DLD1 and SW480 cells were harvested 48 h after siRNA
transfection using TRIzol (Life Technologies, Darmstadt,
Germany). Total RNA was isolated according to the
manufacturer’s instructions and reverse transcribed
using SuperScript II reverse transcriptase (Life Tech-
nologies) according to the instructions provided by the
manufacturer. cDNA was amplified and labeled with
biotin using kits from Affymetrix. Labeled probes were
hybridized to Human Genome U133 Plus 2.0 microar-
rays (Affymetrix), washed, stained and scanned using
equipment from Affymetrix. The microarray analysis
was performed in triplicates for each cell line (see also
the corresponding CEL files that are part of the accom-
panying GEO submission).
Identification of validated β-catenin target genes
We were particularly interested in β-catenin target genes
that are regulated in normal colon or colon carcinoma
cells or colon carcinoma cell lines. For this reason, the
PubMed database was searched using the phrase “beta
catenin AND target AND (colorectal OR colon OR in-
testinal OR intestine)”. 591 articles were identified (as of
June 1st, 2012) and publications were screened for the
identification and characterization of β-catenin target
genes. We were able to identify 66 published β-catenin
target genes that matched our criteria (Table 1). 33 out
of the 66 genes have been published earlier by Nusse
et al. on their web site http://www.stanford.edu/group/
nusselab/cgi-bin/wnt/target_genes (last update: October
2010). These genes are marked with an asterisk after the
gene name (Table 1).
Statistical analysis
For evaluation purposes, we compared genes differentially
expressed in DLD1 and SW480 cells after treatment with
β-catenin siRNA to a previously published data set con-
taining differentially expressed genes after treatment
of the colon carcinoma cell line LS174T with β-catenin
shRNA (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE18560). The software package R (version 2.14.1)
was used for the statistical analysis of the microarray data.
Microarray data were preprocessed using the rma func-
tion from the R package “affy”. The expression matrix was
filtered to contain only those probe sets that can be
assigned to a gene name. Log2 intensity values were usedfor all subsequent analyses. Differentially expressed genes
were identified with the R package “limma”. Genes were
called “differentially expressed” if the corrected p value
(according to Benjamini-Hochberg) was lower than 0.05.
We considered a gene to be significant only if all of its sig-
nificant probe sets were regulated in the same direction.
Genes with significant probe sets that were differently reg-
ulated were not considered significant because we could
not determine if the gene is up- or down regulated.
Gene set enrichment analysis (GSEA)
The gene set enrichment analysis was performed using the
GSEA software [80,81]. Due to the small sample size of
our data sets, we used gene set permutation for the GSEA
analysis. Probe sets belonging to the same gene were col-
lapsed to a gene symbol and 1000 permutations were per-
formed to find differentially expressed gene sets. If our
data sets contained less than 15 genes of a certain gene
set, the gene set was filtered out. After this restriction, 138
out of 217 Biocarta gene sets and 175 out of 186 KEGG
gene sets were analyzed. Gene sets with a false discover
rate (FDR) lower than 0.25 were considered statistically
significant. The corresponding files containing the data of
the GSEA analysis are part of the Additional files. The
names of the directories containing the files were com-
posed of the term ‘GSEA’, the name of the cell line, e.g.
DLD1, SW480, or LS174T, and the pathway database
(KEGG or Biocarta). Please use the files with the name
‘index.html’ in the corresponding directories to start ex-
ploring the data.
KEGG and Biocarta pathways that are regulated similarly
in two or three cell lines were identified using the Biovenn
software (http://www.cmbi.ru.nl/cdd/biovenn/) [118].Network visualization
Gene symbols of β-catenin target genes common to two
or more cell lines were entered in the query function
of the “Michigan molecular interaction” (MiMI) plugin
(version 3.11) in the software package “Cytoscape”
(version 2.83) [119,120]. Using the human database entries
to analyze interactions between all molecule types and
in all data sources, we searched for “Interactions among
query genes”. Only networks that contained three or more
nodes were displayed.Availability of supporting data
The data sets supporting the results of this article are
available NCBI's Gene Expression Omnibus (GEO) re-
pository [121]. The unique identifier for this dataset is
GSE44097. The corresponding information can be found
at the following web site: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE44097.
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Additional file 1: Table S1. Results of the DNA microarray analysis
(all genes). DLD1, SW480, and LS174T cells were treated with siRNA or
shRNA targeting beta-catenin. Differentially expressed genes were identified
using DNA microarrays as described in Materials and Methods. Using the
Biovenn software, genes that are regulated similarly in two or three cell lines
were identified and listed under separate tabs. Accordingly, genes that are
differentially expressed in only one cell line were listed in a separate tab
labeled with the name of the cell line.
Additional file 2: Table S2. Results of the DNA microarray analysis
(focusing on known β-catenin target genes). DLD1, SW480, and LS174T
cells were treated with siRNA or shRNA targeting β-catenin. Microarray
data was re-analyzed focusing our analysis only on the list of these 66
previously published β-catenin target genes. Using the Biovenn software,
genes that are regulated similarly in two or three cell lines were identified
and listed under separate tabs. Accordingly, genes that are differentially
expressed in only one cell line were listed in a separate tab labeled with
the name of the cell line.
Additional file 3: Table S3. Results of the DNA microarray analysis
(focusing on genes encoding bHLH proteins). DLD1, SW480, and LS174T
cells were treated with siRNA or shRNA targeting beta-catenin. Microarray
data was re-analyzed focusing our analysis only on the 96 bHLH proteins
listed in the PFAM database. Using the Biovenn software, genes that are
regulated similarly in two or three cell lines were identified and listed
under separate tabs. Accordingly, genes that are differentially expressed
in only one cell line were listed in a separate tab labeled with the name
of the cell line.
Additional file 4: GSEA analysis using the Biocarta pathway
database. This zipped file contains confirming data of the GSEA analysis.
The names of the directories containing the files were composed of the
term ‘GSEA’, the name of the cell line, e.g. DLD1, SW480, or LS174T, and
the pathway database (Biocarta). Please use a web browser to view the
files with the name ‘index.html’ in the corresponding directories to start
exploring the data.
Additional file 5: GSEA analysis using the KEGG pathway database.
This zipped file contains confirming data of the GSEA analysis. The names
of the directories containing the files were composed of the term ‘GSEA’,
the name of the cell line, e.g. DLD1, SW480, or LS174T, and the pathway
database (KEGG). Please use a web browser to view the files with the name
‘index.html’ in the corresponding directories to start exploring the data.
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